Radius Health has been granted a patent for a method of treating estrogen-dependent cancers, including breast cancer, by administering a combination of RAD1901 and an m-TOR inhibitor like everolimus. The treatment targets specific mutations in estrogen receptors, offering a promising approach for cancer therapy. GlobalData’s report on Radius Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Radius Health, Microneedles for transdermal drug delivery was a key innovation area identified from patents. Radius Health's grant share as of January 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Combination treatment for estrogen-dependent cancers using rad1901 and everolimus
A recently granted patent (Publication Number: US11857518B2) discloses a method for treating breast cancer in patients with estrogen receptor alpha-positive cancer that carries a Y537S mutant estrogen receptor alpha. The method involves administering a combination of an m-TOR inhibitor (sirolimus, temsirolimus, everolimus, or ridafarolimus) and RAD1901, a specific compound structure. This treatment approach is particularly beneficial for drug-resistant breast cancer cases that have shown resistance to antiestrogen and aromatase inhibitor therapies, such as tamoxifen, toremifene, fulvestrant, aromasin, letrozole, and anastrozole.
Furthermore, the patent outlines specific dosages and administration protocols for RAD1901, ranging from 100 mg to 1,000 mg daily, with options for different daily dosages and delivery in two separate equal doses. The method is targeted towards post-menopausal women and suggests identifying suitable candidates for treatment based on increased expression of specific genes related to cancer, including AKT1, AKT2, BRAF, CDK4, CDK6, PIK3CA, PIK3R1, and MTOR. Additionally, the m-TOR inhibitor component of the treatment is recommended to be dosed between 1 mg and 500 mg daily, with everolimus specifically mentioned at doses of 10 mg or within the range of 2.5 mg to 7.5 mg per day, administered once daily. This patent offers a novel and potentially effective therapeutic approach for a specific subset of breast cancer patients with identified genetic mutations and treatment resistance.
To know more about GlobalData’s detailed insights on Radius Health, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
